CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia

This editorial explores a novel strategy combining CD7 targeted CAR T-cell therapy with allogeneic hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory leukemia, particularly AML. Ten patients achieved complete remission post CAR T cell infusion, with most showing minimal residual disease negativity. Subsequent HSCT without conditioning or GVHD prophylaxis led to successful engraftment and durable remission in several cases. The findings suggest CAR T cells may facilitate immune reconstitution and reduce GVHD risk, offering a promising therapeutic pathway for high-risk leukemia.

This editorial explores a novel strategy combining CD7 targeted CAR T-cell therapy with allogeneic hematopoietic stem cell transplantation (HSCT) in patients with relapsed or refractory leukemia, particularly AML. Ten patients achieved complete remission post CAR T cell infusion, with most showing minimal residual disease negativity. Subsequent HSCT without conditioning or GVHD prophylaxis led to successful engraftment and durable remission in several cases. The findings suggest CAR T cells may facilitate immune reconstitution and reduce GVHD risk, offering a promising therapeutic pathway for high-risk leukemia.